EP2759299A1 — Galactosaminogalactan comprising alpha 1-4 linked galactose and alpha 1-4 linked N-acetylgalactosamine for use in the treatment of at least one inflammatory disease
Assigned to Institut Pasteur · Expires 2014-07-30 · 12y expired
What this patent protects
A first object of the invention is galactosaminogalactan comprising α1-4 linked galactose and α1-4 linked N-acetylgalactosamine for use in the treatment of at least one inflammatory disease. Another objet of the invention is a pharmaceutical composition comprising a galactosamino…
USPTO Abstract
A first object of the invention is galactosaminogalactan comprising α1-4 linked galactose and α1-4 linked N-acetylgalactosamine for use in the treatment of at least one inflammatory disease. Another objet of the invention is a pharmaceutical composition comprising a galactosaminogalactan comprising α1-4 linked galactose and α1-4 linked N-acetylgalactosamine as defined in any of the above-cited claims, and optionally a pharmaceutically acceptable carrier. Another object of the invention is a pharmaceutical composition according to the invention, for use in the treatment of at least one inflammatory disease. Another object of the invention is an inhibitor of IL-1 RA for use in the treatment of human fungal diseases. Another object of the invention is a pharmaceutical composition comprising an inhibitor of IL-1 RA, and optionally a pharmaceutically acceptable carrier.
Drugs covered by this patent
- Copiktra (DUVELISIB) · Secura
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.